Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-15 in xeroderma pigmentosum sunburn-enhanced type
jRCT2051210181Completed
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of melatonin in xeroderma pigmentosum (XP) (2 arms). Primary endpoint: Minimum erythema dose at 72 hours. Started Apr 2022; status: completed.
02
Drugs
melatonin
03
Conditions
xeroderma pigmentosum (XP)
Beyond the preview
Go deeper on jRCT2051210181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210181.